Enterprise Value
36.73M
Cash
8.884M
Avg Qtr Burn
-10.71M
Short % of Float
1.49%
Insider Ownership
15.78%
Institutional Own.
66.68%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AXA1125 Details COVID-19 | Phase 2/3 Initiation | |
AXA1125 Details Non-alcoholic steatohepatitis , Fatty liver disease, Liver disease | Failed Discontinued | |
AXA1665 Details Liver disease, Overt hepatic encephalopathy | Failed Discontinued |